(Effective as from 1 April 2012 and amended on 30 August 2013 and 18 December 2025) (自2012 年4 月1日起生效及於 2013 年8 月30 日及 2025 年 12 月 18 日修訂) GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大成生化科技集團有限公司 董事會提名委員會職權範圍 Terms of reference of the Nomination Committee of the Board of Directors GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大成生化科技集團有限公司 (the "Company" and "本公司") Terms of reference of the Nomination Committee (the "Committee") of the Board (the "Board") of Directors (the "Directors") of the Company ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 大成生化科技集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00809 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.1 | HKD | | 3,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 30,000,000,000 | HKD | | | 0.1 HKD | | 3,000,000,00 ...

Investment Rating - The report does not explicitly state an investment rating for Global Bio-chem Technology Group (0809.HK) Core Insights - The company reported a net loss of HKD 155 million for the first half of 2025, despite a revenue increase of 32.0% year-on-year to HKD 1.186 billion and a gross profit increase of 144.2% to HKD 161 million [1][6] - The company is committed to debt capitalization and has successfully capitalized approximately HKD 301 million of supplier debt, reducing the total by about 34.72% [4][20] - The company aims to lower lysine production costs and plans to complete a boiler renovation project by August 2026 [4][20] - The company is exploring partnerships or investors to enhance operational efficiency and restore production at its Xinglongshan facility [4][20] Summary by Sections Latest Developments - In the first half of 2025, the company achieved revenues of HKD 1.186 billion, a 32.0% increase year-on-year, and a gross profit of HKD 161 million, a 144.2% increase year-on-year [1][6] - The EBITDA for the period was approximately HKD 82.3 million, down from HKD 102 million in the previous year, primarily due to the absence of a one-time government subsidy [1][6] Business Strategy - The company has completed a share issuance to capitalize on supplier debt, resulting in the conversion of HKD 4.61 billion in supplier debt to equity [4][20] - The company is focused on reducing lysine production costs through process optimization and aims to complete a boiler renovation project by August 2026 [4][20] - The company is actively seeking business alliances or investors to enhance operational efficiency and restore production at its Xinglongshan facility [4][20] Market Position - The company is a pioneer in corn refining and biochemical product manufacturing in Asia, with a goal to become the largest integrated manufacturer of corn-based biochemical products in the Asia-Pacific region [5][6] - The company has seen a significant increase in the sales volume of its amino acid segment, which rose by approximately 52.0% to about 187,000 tons [6][10] - The average operating rate for corn starch production in China reached 69.26% in 2024, up from 61.67% in 2023, indicating a positive trend in the upstream corn refining sector [11][12] Financial Performance - The gross profit margin improved from 7.3% in the first half of 2024 to 13.6% in the first half of 2025, reflecting enhanced operational efficiency [16][17] - The company’s administrative and other expenses decreased significantly following the sale of a subsidiary, contributing to improved cash flow and liquidity [16][17] Industry Trends - The global corn production for the 2025/26 season is projected to increase to 1.264 billion tons, driven by expanded planting areas in the U.S. [11][12] - Domestic corn prices in China have been rising steadily, with prices increasing from RMB 2,075 per ton in January 2025 to RMB 2,447 per ton by June 2025 [12][16] - The lysine market is experiencing volatility due to international trade policy uncertainties, with a 5.0% decline in China's lysine export volume in the first half of 2025 [17][18]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 大成生化科技集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00809 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.1 | HKD | | 3,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 30,000,000,000 | HKD | | | 0.1 HKD | | 3,000,000,00 ...

Core Points - The company announced that all conditions precedent under Share Purchase Agreement I and Share Purchase Agreement II have been fulfilled, and the agreements were completed on October 2, 2025 [1] - A total of 2.753 billion shares were issued as consideration shares [1] - The company received a conversion notice from bondholders to fully exercise their conversion rights under the convertible bond, converting HKD 1.086 billion principal amount into 5.173 billion conversion shares at a conversion price of HKD 0.21 per share [1] - After completing the necessary administrative procedures for the issuance of conversion shares, the company issued 5.173 billion conversion shares to bondholders on October 2, 2025, which rank equally with all other existing shares [1]

Core Viewpoint - The company has successfully completed the share purchase agreements, resulting in the issuance of a total of 2.753 billion shares [1] Group 1: Share Purchase Agreements - The board of directors announced that all conditions precedent for Share Purchase Agreement I and Share Purchase Agreement II have been met [1] - The share purchase agreements were completed on October 2, 2025 [1] - A total of 2.753 billion shares have been issued as consideration shares [1] Group 2: Convertible Bonds - The company received a conversion notice from bondholders regarding the full exercise of their conversion rights under the convertible bond issue [1] - The principal amount of HKD 1.086 billion in convertible bonds was converted into 5.173 billion shares at a conversion price of HKD 0.21 per share [1] - After completing the necessary administrative procedures for the issuance of conversion shares, the company issued 5.173 billion conversion shares to bondholders on October 2, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 大成生化科技集團有限公司 呈交日期： 2025年10月2日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | | 00809 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大 成 生 化 科 技 集 團 有 限 公 司 * （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：00809） 完成根據特別授權發行代價股份 及 於完成後，總額約人民幣461.1百萬元的供應商債務（經整體折減約34.72%後，最終金額 為人民幣301,007,373元）已悉數資本化。目標公司成為本公司的直接全資附屬公司，而 世紀大成再次成為本公司的間接全資附屬公司。為免生疑問，於供應商債務重組安排過 程中，世紀大成的財務業績、資產及負債一直併入本公司的綜合財務報表。有關供應商 債務重組安排的詳情，請參閱該通函。 轉換可換股債券 轉換可換股債券 完成根據特別授權發行代價股份 茲提述大成生化科技集團有限公司（「本公司」）日期為二零二五年七月八日之公告及本公 司日期為二零二五年八月二 ...

致：香港交易及結算所有限公司 公司名稱: 大成生化科技集團有限公司 呈交日期: 2025年10月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00809 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.1 | HKD | | 3,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 30,000,000,000 | HKD | | | 0.1 HKD | | 3,000,000,000 | | 2. 股份分類 | 優先股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 否 | | | --- ...

（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：00809） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大 成 生 化 科 技 集 團 有 限 公 司 * 於股東特別大會上 提呈決議案的投票結果 董事會欣然宣佈，於股東特別大會上提呈的普通決議案已以按股數投票方式正式通 過。 謹此提述大成生化科技集團有限公司（「本公司」）於二零二五年八月二十九日刊發的通函 （「該通函」）。除文義另有所指外，本公告所用詞彙與該通函所界定者具有相同涵義。 於股東特別大會上的投票結果 董事會欣然宣佈，載列於日期為二零二五年八月二十九日的股東特別大會通告（「股東特 別大會通告」）的普通決議案（「決議案」）投票結果如下： — 1 — | 決議案 | 實際投票票數(%) | | | --- | --- | --- | | | 贊成 | 反對 | | ...